INTS - INTENSITY THERAPEUTICS, INC.

5.3
-0.020   -0.377%

Share volume: 59,820
Last Updated: 04-17-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: 0.23%

PREVIOUS CLOSE
CHG
CHG%
$5.32
-0.02
0.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
34%
Profitability 35%
Dept financing 29%
Liquidity 50%
Performance 30%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-1.12%
1 Month
-16.27%
3 Months
1,227.32%
6 Months
1,802.37%
1 Year
173.20%
2 Year
36.60%
Key data
Stock price
$5.30
P/E Ratio 
N/A
DAY RANGE
$5.20 - $5.42
EPS 
-$2.75
52 WEEK RANGE
$0.19 - $8.06
52 WEEK CHANGE
$173.20
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
2.541 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-08-2025
BETA 
1.47
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$26,633
AVERAGE 30 VOLUME 
$26,372
Company detail
CEO: Lewis H. Bender
Region: US
Website: intensitytherapeutics.com
Employees: 2
IPO year: 2023
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Intensity Therapeutics, Inc. is a clinical stage biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction leading to anti-cancer immune activation. Our new approach involves the direct injection into tumors of a unique product created from our DfuseRx℠ discovery platform. Our principal executive offices are located at 61 Wilton Road, 3rd Floor, Westport, CT.

Recent news